A red, itchy rash spread across the man's arms and chest, then worsened into erythroderma, a severe, widespread skin ...

Lynk Pharmaceuticals shares encouraging topline data from Phase III trials of Zemprocitinib, showing promise in treating rheumatoid arthritis patients effectively.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), a clinical stage innovative drug development company focused on developing innovative therapies for immune and ...

DermTech 2.0 ("DermTech LLC" or "The Company"), a leader in precision dermatology enabled by DermTech's proprietary non-invasive Smart Sticker® skin sample collection platform, announced today the ...

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative ...

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA- , povorcitinib, ILUMYA®, ODOMZO- , REMICADE- , ...

This a men’s “sober house,” one of the first in the nation exclusively for gambling addicts. Adam has been here since it ...

Guardant Health, Inc. , a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Vitiligo is a long-term skin condition where certain areas lose their natural color and turn noticeably lighter than the ...